Operating Segments

6 Months Ended

Jun. 30, 2023

Operating Segments

Operating Segments

Note 11. Operating Segments

The Company maintains two active operating segments: Specialized BioTherapeutics and Public Health Solutions. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended
	June 30,
	2023		2022
Revenues
Specialized BioTherapeutics	$	68,505	$	—
Public Health Solutions		138,424		228,640
Total	$	206,929	$	228,640
Income (loss) from Operations
Specialized BioTherapeutics	$	(611,300)	$	(2,000,350)
Public Health Solutions		(2,247)		(1,002)
Corporate		(1,016,777)		(1,393,944)
Total	$	(1,630,324)	$	(3,395,296)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	954	$	2,783
Public Health Solutions		159		463
Corporate		477		5,266
Total	$	1,590	$	8,512
Other (Expense) Income, Net
Specialized BioTherapeutics	$	9,931	$	68,509
Corporate		8,369		(214,908)
Total	$	18,300	$	(146,399)
Share-Based Compensation
Specialized BioTherapeutics	$	27,427	$	28,343
Public Health Solutions		994		1,054
Corporate		61,621		42,273
Total	$	90,042	$	71,670

	Six Months Ended
	June 30,
	2023		2022
Revenues
Specialized BioTherapeutics	$	223,870	$	—
Public Health Solutions		240,237		416,703
Total	$	464,107	$	416,703
Income (loss) from Operations
Specialized BioTherapeutics	$	(1,521,677)	$	(3,540,078)
Public Health Solutions		(1,820)		(121,623)
Corporate		(2,257,516)		(3,925,981)
Total	$	(3,781,013)	$	(7,587,682)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	2,025	$	5,397
Public Health Solutions		337		899
Corporate		1,013		10,448
Total	$	3,375	$	16,744
Other (Expense) Income, Net
Specialized BioTherapeutics	$	16,013	$	123,588
Corporate		(54,330)		(426,622)
Total	$	(38,317)	$	(303,034)
Share-Based Compensation
Specialized BioTherapeutics	$	54,854	$	56,847
Public Health Solutions		1,988		2,108
Corporate		106,834		90,986
Total	$	163,676	$	149,941

	As of		As of
	June 30,		December 31,
	2023		2022
Identifiable Assets
Specialized BioTherapeutics	$	79,830	$	103,742
Public Health Solutions		118,791		121,290
Corporate		13,627,632		14,054,685
Total	$	13,826,253	$	14,279,717